| pubmed-article:2790673 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2790673 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:2790673 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:2790673 | lifeskim:mentions | umls-concept:C0042670 | lld:lifeskim |
| pubmed-article:2790673 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:2790673 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2790673 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:2790673 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:2790673 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:2790673 | pubmed:dateCreated | 1989-11-1 | lld:pubmed |
| pubmed-article:2790673 | pubmed:abstractText | Nineteen patients with advanced malignant melanoma were treated with a combination of recombinant alfa-interferon (alpha-IFN) and vinblastine (VBL). The alpha-IFN was administered subcutaneously daily at an initial dose of 3 X 10(6) IU escalating to a maximal dose of 9 X 10(6) U daily for the first 10 weeks followed by 3 X/week for 6 months. The VBL was given once every week at a dose of 0.025 mg/kg. Of the 19 patients 17 were evaluable for tumor response. Thirteen patients had received chemotherapy previously. Median performance status (World Health Organization) was 0, ranging from 0 to 2. One complete response and one partial response was observed. All patients experienced flu-like symptoms attributed to alpha-IFN. Leukopenia was observed in 12 patients and a planned dose escalation of VBL was undertaken for the patients only. It is concluded that combined alpha-IFN and VBL is only marginally effective in patients with advanced malignant melanoma who have had prior chemotherapy. | lld:pubmed |
| pubmed-article:2790673 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2790673 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2790673 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2790673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2790673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2790673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2790673 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2790673 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2790673 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:2790673 | pubmed:author | pubmed-author:GundersenSS | lld:pubmed |
| pubmed-article:2790673 | pubmed:author | pubmed-author:FlokkmannAA | lld:pubmed |
| pubmed-article:2790673 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2790673 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2790673 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:2790673 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2790673 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2790673 | pubmed:pagination | 1617-9 | lld:pubmed |
| pubmed-article:2790673 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:meshHeading | pubmed-meshheading:2790673-... | lld:pubmed |
| pubmed-article:2790673 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2790673 | pubmed:articleTitle | Interferon in combination with vinblastine in advanced malignant melanoma. A phase I-II study. | lld:pubmed |
| pubmed-article:2790673 | pubmed:affiliation | Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo. | lld:pubmed |
| pubmed-article:2790673 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2790673 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
